Physician profile
John Patrick Welsh
NPI 1881606168
$3,208.29
in general payments reported to CMS, 2019-2025
21 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $32.21 · 2021: $40.14 · 2022: $181 · 2023: $384 · 2024: $1,024 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,492.19 |
| Education | $264.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $613.72 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $541.11 | 2022-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $390.05 | 2023-2025 | Ilumya |
| Genzyme Corporation | $387.67 | 2023-2025 | |
| Prugen, INC. Pharmaceuticals | $158.29 | 2019 | |
| Leo Pharma INC. | $150.98 | 2024-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $149.33 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $148.78 | 2023-2025 | Libtayo, Dupixent |
| Incyte Corporation | $120.24 | 2023-2025 | Opzelura |
| Pfizer INC. | $107.15 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $85.62 | 2019-2023 | |
| Lilly USA, LLC | $73.18 | 2025 | Taltz, Ebglyss |
| Amgen INC. | $65.67 | 2019-2025 | Otezla, Otezla |
| Biofrontera INC. | $52.53 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| E.R. Squibb & Sons, L.L.C. | $42.30 | 2024 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $25.25 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $24.25 | 2023 | |
| Almirall LLC | $22.24 | 2023 | Seysara |
| Galderma Laboratories, L.P. | $19.45 | 2024 | |
| Dermira, INC. | $16.44 | 2020 | |
| Ucb, INC. | $14.04 | 2024 | Bimzelx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Welsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.